Cell and Gene Therapies in Rare Disorders Market

Market Research Report

A quick peek into the report

1.1   Introduction
1.2   Market Trends
1.3   Regulatory Framework
1.4   Epidemiology Analysis
1.5   Clinical Trial Analysis
1.6   Market Dynamics
1.6.1   Impact Analysis
1.6.2   Market Drivers
1.6.3   Market Challenges
1.6.4   Market Opportunities

2.1   North America
2.1.1   Key Findings
2.1.2   Market Dynamics
2.1.3   Market Sizing and Forecast
2.1.3.1   North America Cell and Gene Therapies in Rare Disorders Market, by Country
2.1.3.1.1   U.S.
2.1.3.1.2   Canada
2.2   Europe
2.2.1   Key Findings
2.2.2   Market Dynamics
2.2.3   Market Sizing and Forecast
2.2.3.1   Europe Cell and Gene Therapies in Rare Disorders Market, by Country
2.2.3.1.1   Germany
2.2.3.1.2   U.K.
2.2.3.1.3   France
2.2.3.1.4   Italy
2.2.3.1.5   Spain
2.2.3.1.6   Rest-of-Europe
2.3   Asia Pacific
2.3.1   Key Findings
2.3.2   Market Dynamics
2.3.3   Market Sizing and Forecast
2.3.3.1   Asia Pacific Cell and Gene Therapies in Rare Disorders Market, by Country
2.3.3.1.1   China
2.3.3.1.2   Japan
2.3.3.1.3   India
2.3.3.1.4   South Korea
2.3.3.1.5   Australia
2.3.3.1.6   Rest-of- Asia Pacific
2.4   Rest of the World
2.4.1   Key Findings
2.4.2   Market Dynamics
2.4.3   Market Sizing and Forecast

3.1   Key Strategies and Development
3.1.1   Mergers and Acquisitions
3.1.2   Synergistic Activities
3.1.3   Business Expansions and Funding
3.1.4   Product Launches and Approvals
3.1.5   Other Activities
3.2   Company Profiles
3.2.1   F. Hoffmann-La Roche Ltd
3.2.1.1   Overview
3.2.1.2   Top Products / Product Portfolio
3.2.1.3   Top Competitors
3.2.1.4   Target Customers/End-Users
3.2.1.5   Key Personnel
3.2.1.6   Analyst View
3.2.2   Bayer AG
3.2.2.1   Overview
3.2.2.2   Top Products / Product Portfolio
3.2.2.3   Top Competitors
3.2.2.4   Target Customers/End-Users
3.2.2.5   Key Personnel
3.2.2.6   Analyst View
3.2.3   Johnson & Johnson
3.2.3.1   Overview
3.2.3.2   Top Products / Product Portfolio
3.2.3.3   Top Competitors
3.2.3.4   Target Customers/End-Users
3.2.3.5   Key Personnel
3.2.3.6   Analyst View
3.2.4   Pfizer Inc.
3.2.4.1   Overview
3.2.4.2   Top Products / Product Portfolio
3.2.4.3   Top Competitors
3.2.4.4   Target Customers/End-Users
3.2.4.5   Key Personnel
3.2.4.6   Analyst View
3.2.5   Sangamo Therapeutics
3.2.5.1   Overview
3.2.5.2   Top Products / Product Portfolio
3.2.5.3   Top Competitors
3.2.5.4   Target Customers/End-Users
3.2.5.5   Key Personnel
3.2.5.6   Analyst View
3.2.6   4D Molecular Therapeutics
3.2.6.1   Overview
3.2.6.2   Top Products / Product Portfolio
3.2.6.3   Top Competitors
3.2.6.4   Target Customers/End-Users
3.2.6.5   Key Personnel
3.2.6.6   Analyst View
3.2.7   Astellas Gene Therapies
3.2.7.1   Overview
3.2.7.2   Top Products / Product Portfolio
3.2.7.3   Top Competitors
3.2.7.4   Target Customers/End-Users
3.2.7.5   Key Personnel
3.2.7.6   Analyst View
3.2.8   GenSight Biologics
3.2.8.1   Overview
3.2.8.2   Top Products / Product Portfolio
3.2.8.3   Top Competitors
3.2.8.4   Target Customers/End-Users
3.2.8.5   Key Personnel
3.2.8.6   Analyst View
3.2.9   Coave Therapeutics
3.2.9.1   Overview
3.2.9.2   Top Products / Product Portfolio
3.2.9.3   Top Competitors
3.2.9.4   Target Customers/End-Users
3.2.9.5   Key Personnel
3.2.9.6   Analyst View
3.2.10   REGENXBIO
3.2.10.1   Overview
3.2.10.2   Top Products / Product Portfolio
3.2.10.3   Top Competitors
3.2.10.4   Target Customers/End-Users
3.2.10.5   Key Personnel
3.2.10.6   Analyst View
3.2.11   Sarepta Therapeutics
3.2.11.1   Overview
3.2.11.2   Top Products / Product Portfolio
3.2.11.3   Top Competitors
3.2.11.4   Target Customers/End-Users
3.2.11.5   Key Personnel
3.2.11.6   Analyst View
3.2.12   Capricor Therapeutics
3.2.12.1   Overview
3.2.12.2   Top Products / Product Portfolio
3.2.12.3   Top Competitors
3.2.12.4   Target Customers/End-Users
3.2.12.5   Key Personnel
3.2.12.6   Analyst View
3.2.13   Brainstorm Cell Therapeutics
3.2.13.1   Overview
3.2.13.2   Top Products / Product Portfolio
3.2.13.3   Top Competitors
3.2.13.4   Target Customers/End-Users
3.2.13.5   Key Personnel
3.2.13.6   Analyst View
3.2.14   Plasmatech Biopharmaceuticals (Abeona Therapeutics)
3.2.14.1   Overview
3.2.14.2   Top Products / Product Portfolio
3.2.14.3   Top Competitors
3.2.14.4   Target Customers/End-Users
3.2.14.5   Key Personnel
3.2.14.6   Analyst View

Research Methodology

Table:   Market Snapshot
Table:   Market Dynamics
Table:   Global Cell and Gene Therapies in Rare Disorders Market (by Region), $Million, 2025-2036

Figure:   Cell and Gene Therapies in Rare Disorders Market (by Scenario), $Million, 2025, 2030, and 2036
Figure:   Global Cell and Gene Therapies in Rare Disorders Market, 2025 and 2036
Figure:   Global Cell and Gene Therapies in Rare Disorders Market Key Trends, Impact Analysis
Figure:   North America Cell and Gene Therapies in Rare Disorders Market, $Million, 2025-2036
Figure:   Europe Cell and Gene Therapies in Rare Disorders Market, $Million, 2025-2036
Figure:   Asia-Pacific Cell and Gene Therapies in Rare Disorders Market, $Million, 2025-2036
Figure:   Rest-of-the-World Cell and Gene Therapies in Rare Disorders Market, $Million, 2025-2036

Cell and Gene Therapies in Rare Disorders Market Report Coverage

Cell and Gene Therapies in Rare Disorders Market
Base Year	2025	Market Size in 2026	$XX Billion
Forecast Period	2026-2036	Value Projection and Estimation by 2036	$XX Billion
CAGR During Forecast Period	XX%

Some of the prominent names in the market are:

• F. Hoffmann-La Roche Ltd
• Bayer AG
• Johnson & Johnson
• Pfizer Inc.
• Sangamo Therapeutics
• 4D Molecular Therapeutics
• GenSight Biologics
• Coave Therapeutics
• REGENXBIO
• Sarepta Therapeutics
• Capricor Therapeutics
• Brainstorm Cell Therapeutics
• Plasmatech Biopharmaceuticals (Abeona Therapeutics)

How can this report add value to the organization?

Product/Innovation Strategy: The report offers in-depth insights into the latest technological advancements in Cell and Gene Therapies in Rare Disorders, enabling organizations to drive innovation and develop cutting-edge products tailored to market needs.

Growth/Marketing Strategy: By providing comprehensive market analysis and identifying key growth opportunities, the report equips organizations with the knowledge to craft targeted marketing strategies and expand their market presence effectively.

Competitive Strategy: The report includes a thorough competitive landscape analysis, helping organizations understand their competitors’ strengths and weaknesses and allowing them to strategize effectively to gain a competitive edge in the market.

Investment and Business Expansion Strategy: By analyzing market trends, funding patterns, and partnership opportunities, the report assists organizations in making informed investment decisions and identifying potential M&A opportunities for business growth.

Introduction to Cell and Gene Therapies in Rare Disorders Market

Cell and gene therapies in rare disorders represent a groundbreaking approach to treating genetic diseases that have traditionally lacked effective treatments. These therapies work by modifying a patient's cells or genes to address the underlying causes of disorders. Gene therapy involves the introduction, alteration, or replacement of genetic material within a patient’s cells to correct genetic mutations, potentially offering a permanent cure. In contrast, cell therapy focuses on transplanting or modifying cells to replace damaged tissue or correct dysfunction.

These therapies are particularly beneficial for rare genetic disorders like hemophilia, Duchenne muscular dystrophy, sickle cell anemia, and retinal diseases, offering hope for long-term or even one-time cures. The market for these therapies is rapidly growing, driven by advancements in gene-editing technologies like CRISPR/Cas9 and innovative vector systems for gene delivery. As regulatory support increases and technologies continue to improve, cell and gene therapies are set to revolutionize the treatment of rare genetic disorders, providing patients with options that were previously unavailable.

One of the key drivers of the cell and gene therapies in rare disorders market is the increasing unmet medical need for effective treatments for rare genetic diseases. Many rare disorders, such as Duchenne muscular dystrophy, hemophilia, and sickle cell disease, have limited or no treatment options, making them challenging to manage with traditional therapies. Cell and gene therapies offer the potential for curative treatments, addressing the root cause of these diseases by modifying genes or cells to correct genetic defects. This capability to provide long-lasting or permanent solutions is driving significant interest and investment in the market, as both healthcare providers and patients seek better options for these life-altering conditions.

Despite the growth of the cell and gene therapies in rare disorders market, several challenges persist that hinder its full potential. One of the major challenges is the high cost of developing and delivering these therapies. Gene therapies are expensive to produce, often costing millions of dollars per patient, which limits accessibility, especially in low- and middle-income regions. Another significant challenge is the complexity of manufacturing these therapies at scale. Gene and cell therapies often involve intricate, patient-specific processes that can be difficult to scale and maintain quality across large production runs.

Additionally, regulatory hurdles continue to present challenges, as different countries have varying regulatory standards and approval timelines for gene therapies. This can delay access to innovative treatments in certain regions. There is also safety concerns related to gene therapy, such as the risk of immune responses to viral vectors or unintended genetic changes that could lead to adverse effects. Furthermore, long-term efficacy and safety data are still limited, as many gene therapies are relatively new, and more extensive studies are needed to fully understand their impact over time. Lastly, patient adherence can be an issue, particularly for therapies that require complex administration processes or frequent monitoring.

These challenges underscore the need for ongoing innovation, cost reduction strategies, regulatory harmonization, and patient education to unlock the full potential of cell and gene therapies in treating rare disorders.

The global cell and gene therapies in rare disorders market is highly competitive, with several major companies actively involved in developing innovative therapies to address rare genetic diseases. These companies, such as F. Hoffmann-La Roche Ltd, Bayer AG, Johnson & Johnson, Pfizer Inc., and Sangamo Therapeutics, are at the forefront of advancing gene-editing technologies, cell-based therapies, and viral vector delivery systems. Their efforts focus on providing curative solutions for conditions like Duchenne muscular dystrophy, hemophilia, sickle cell disease, and retinal dystrophies. With the potential for one-time treatments and the ability to modify genes at the molecular level, these companies are pioneering new treatments that offer lasting benefits to patients. As the market continues to grow, these key players are competing to capture market share and push the boundaries of what is possible in gene and cell therapy.

The global cell and gene therapies in rare disorders market is experiencing several key emerging trends. One significant trend is the advancement of gene-editing technologies, particularly CRISPR/Cas9. This innovative technology allows for precise and targeted modifications of the DNA within a patient's cells, enabling the potential to cure genetic disorders at their root cause. As gene-editing techniques become more refined, they offer the promise of permanent, one-time treatments for rare diseases that were previously untreatable. This trend is driving significant growth in the market, with numerous companies developing therapies that leverage these cutting-edge technologies to address unmet medical needs in rare genetic conditions.

Cell and Gene Therapies in Rare Disorders Market - A Global and Regional Analysis

Focus on Country and Region - Analysis and Forecast, 2026-2036
This report will be delivered in 7-10 working days.

Schedule a Call

Some Faq's

Frequently Asked Questions

Ans: The global cell and gene therapies in rare disorders market was valued at approximately USD XX billion in 2023 and is projected to reach USD XX billion by 2035, exhibiting a compound annual growth rate (CAGR) of approx. XX% from 2025 to 2035.

Ans: Major players in the global cell and gene therapies in rare disorders market include Pfizer Inc., F. Hoffmann-La Roche Ltd etc.

Ans: Trends:
• Personalized Medicine: Tailoring gene therapies to individual genetic profiles is becoming more prevalent, aiming to improve efficacy and minimize adverse effects.
• Combination Therapies: Integrating gene therapies with existing treatments, such as immunotherapies, is gaining traction to enhance therapeutic outcomes.
• Global Expansion: Efforts are underway to increase access to gene therapies in emerging markets, addressing the global burden of rare diseases.
• Platform Technologies: Development of universal gene therapy platforms that can be adapted for multiple disorders is a growing area of interest.

Driver:
• Technological Advancements: Innovations in CRISPR/Cas9 gene editing and viral vector development have enhanced the precision and efficiency of gene therapies, expanding their applicability to a broader range of rare disorders
• Regulatory Support: Accelerated approval pathways and increased collaboration between regulatory agencies and biopharmaceutical companies have expedited the development and availability of gene therapies.
• Unmet Medical Needs: The lack of effective treatments for many rare genetic disorders has created a significant demand for innovative therapies, driving investment and research in this area.
• One-Time Treatment Potential: Gene therapies offer the possibility of long-term or permanent cures with a single administration, appealing to both patients and healthcare providers.

Ans:
• High Treatment Costs: The substantial cost of gene therapies, exemplified by treatments like Elevidys priced at $3.2 million, poses accessibility challenges.
• Manufacturing Complexities: Scalability and consistency in production remain significant hurdles in gene therapy development.
• Long-Term Safety Data: The need for extensive long-term studies to assess the safety and efficacy of gene therapies in diverse populations.

Ans:
• Advancements in Manufacturing and Scalability: Reducing production costs and improving scalability to make treatments more affordable.
• Investment in R&D: Increased funding for gene editing, vector development, and clinical trials in rare diseases.
• Clinical Trial Expansions: Expanding clinical trials for new gene therapies, increasing market awareness and access.

A quick peek into the report

Table of Contents

Cell and Gene Therapies in Rare Disorders Market Report Coverage

How can this report add value to the organization?

Introduction to Cell and Gene Therapies in Rare Disorders Market

$4900

Cell and Gene Therapies in Rare Disorders Market - A Global and Regional Analysis

Frequently Asked Questions

Cell and Gene Therapies in Rare Disorders Market - A Global and Regional Analysis

A quick peek into the report

Table of Contents

1 Global Cell and Gene Therapies in Rare Disorders Market: Industry Outlook

2 Global Cell and Gene Therapies in Rare Disorders Market (by Region), ($Million), 2025-2036

3 Global Cell and Gene Therapies in Rare Disorders Market: Competitive Landscape and Company Profiles

4 Research Methodology

List of Tables

List of Figures

Cell and Gene Therapies in Rare Disorders Market Report Coverage

How can this report add value to the organization?

Introduction to Cell and Gene Therapies in Rare Disorders Market

$4900

Cell and Gene Therapies in Rare Disorders Market - A Global and Regional Analysis

Frequently Asked Questions

Q: What is the current cell and gene therapies in rare disorders market size and growth rate?

Q: Who are the key players in the cell and gene therapies in rare disorders market?

Q: What are the major cell and gene therapies in rare disorders market trends and drivers?

Q: What challenges or restraints are affecting the cell and gene therapies in rare disorders market?

Q: What are the opportunities for growth in the cell and gene therapies in rare disorders market?